Evidence map›Paper›PMID 39485038›Full record

ArticleCancer research communications2024

Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer.

Slavica Dimitrieva, Jon M Harrison, Jonathan Chang, Michelle Piquet, Mari Mino-Kenudson, Millicent Gabriel, Vivek Sagar, Heiko Horn, Kasper Lage, Julie Kim and 24 more

Abstract read
In one paragraph

Article in Cancer research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Slavica Dimitrieva *Oncology Data Science, Novartis Biomedical Research, Basel, Switzerland.ORCID 0000-0002-0043-2677
Jon M Harrison *Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-4416-8086
Jonathan Chang *Oncology Translational Research, Novartis Biomedical Research, Cambridge, Massachusetts.ORCID 0000-0001-6894-7127
Michelle PiquetOncology Innovative Targets and Technologies, Novartis Biomedical Research, Cambridge, Massachusetts.ORCID 0000-0003-1515-0442
Mari Mino-KenudsonDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-9092-2265
Millicent GabrielOncology Innovative Targets and Technologies, Novartis Biomedical Research, Cambridge, Massachusetts.ORCID 0009-0005-2185-0519
Vivek SagarOncology Data Science, Novartis Biomedical Research, Cambridge, Massachusetts.ORCID 0009-0002-4794-3682
Heiko HornDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-4898-0557
Kasper LageDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-6827-6239
Julie KimOncology Innovative Targets and Technologies, Novartis Biomedical Research, Cambridge, Massachusetts.ORCID 0009-0004-9434-7298
Gang LiOncology Data Science, Novartis Biomedical Research, Basel, Switzerland.ORCID 0000-0001-6778-2842
Shaobu WengOncology Translational Research, Novartis Biomedical Research, Cambridge, Massachusetts.ORCID 0009-0004-0830-2481
Cynthia HarrisDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0009-0007-3059-5681
Anupriya S KulkarniMass General Cancer Center, Boston, Massachusetts.ORCID 0009-0008-2653-2052
David T TingMass General Cancer Center, Boston, Massachusetts.ORCID 0000-0002-3261-2322
Motaz QadanDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-6951-8308
Peter J FagenholzDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-7787-0317
Cristina R FerroneDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-6295-1085
Angelo L GrauelOncology Data Science, Novartis Biomedical Research, Cambridge, Massachusetts.ORCID 0000-0003-1403-2903
Tyler LaszewskiOncology Translational Research, Novartis Biomedical Research, Cambridge, Massachusetts.ORCID 0000-0002-3544-5566
Alina RazaOncology Translational Research, Novartis Biomedical Research, Cambridge, Massachusetts.ORCID 0009-0000-1447-8927
Markus RiesterOncology Data Science, Novartis Biomedical Research, Cambridge, Massachusetts.ORCID 0000-0002-4759-8332
Tim SomervilleOncology Innovative Targets and Technologies, Novartis Biomedical Research, Cambridge, Massachusetts.ORCID 0000-0002-6295-6126
Joel P WagnerOncology Data Science, Novartis Biomedical Research, Cambridge, Massachusetts.ORCID 0000-0001-6579-2908
Glenn DranoffOncology, Novartis Biomedical Research, Cambridge, Massachusetts.ORCID 0000-0002-2341-7517
Jeffrey A EngelmanOncology, Novartis Biomedical Research, Cambridge, Massachusetts.ORCID 0009-0004-0775-4523
Audrey KauffmannOncology Data Science, Novartis Biomedical Research, Basel, Switzerland.ORCID 0000-0002-5560-4210
Rebecca LearyOncology Translational Research, Novartis Biomedical Research, Cambridge, Massachusetts.ORCID 0000-0003-4274-4836
Andrew L WarshawDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-7788-3110
Keith D LillemoeDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0009-0004-5057-3875
Carlos Fernández-Del CastilloDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-5975-7225
David A RuddyOncology Innovative Targets and Technologies, Novartis Biomedical Research, Cambridge, Massachusetts.ORCID 0000-0001-8244-5609
Andrew S LissDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-4040-9172
Viviana CremascoOncology Translational Research, Novartis Biomedical Research, Cambridge, Massachusetts.ORCID 0000-0001-8666-2467

Funding

Epigenetic regulation of pancreatic cancer subtype identity and tumorigenesis by PHF2R01CA272876 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Andrew Liss · 2023 to 2026
$1.5M
Epigenetic Regulation of Hemidesmosome Signaling in Pancreatic CancerR03CA241971 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI LISS, ANDREW · 2020 to 2020
$166k
NCI NIH HHS R01 CA272876NCI NIH HHS R03 CA241971
6 · The paper itself

Abstract

abstractCancer progression and response to therapy are inextricably reliant on the coevolution of a supportive tissue microenvironment. This is particularly evident in pancreatic ductal adenocarcinoma, a tumor type characterized by expansive and heterogeneous stroma. Herein, we employed single-cell RNA sequencing and spatial transcriptomics of normal, inflamed, and malignant pancreatic tissues to contextualize stromal dynamics associated with disease and treatment status, identifying temporal and spatial trajectories of fibroblast differentiation. Using analytical tools to infer cellular communication, together with a newly developed assay to annotate genomic alterations in cancer cells, we additionally explored the complex intercellular networks underlying tissue circuitry, highlighting a fibroblast-centric interactome that grows in strength and complexity in the context of malignant transformation. Our study yields new insights on the stromal remodeling events favoring the development of a tumor-supportive microenvironment and provides a powerful resource for the exploration of novel points of therapeutic intervention in pancreatic ductal adenocarcinoma. SIGNIFICANCE: Pancreatic cancer remains a high unmet medical need. Understanding the interactions between stroma and cancer cells in this disease may unveil new opportunities for therapeutic intervention.

Indexed as

Pancreatic NeoplasmsSingle-Cell AnalysisFibroblastsHumansSequence Analysis, RNATumor Microenvironment

Identifiers

PMID39485038
PMCPMC11609929

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.